ERBB2 and breast carcinoma: However, the number of HER2‐positive patients with breast cancer contained in this microarray was only nine (6.4% of 140 cases), which was significantly lower than that in the epidemiological study.35 Therefore, it was essential for us to further verify the overexpression of FLI‐1 in the HER2‐positive subtype.